Risk of progression of nephropathy in a population-based sample with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 91, Issue 2, 2011, Pages 246-252

  Vupputuri, S ^a   Nichols, G A ^b   Lau, H ^c   Joski, P ^a   Thorp, M L ^d  

^a KAISER PERMANENTE   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Northwest Permanente ^*  (United States)

Author keywords

Albuminuria; Diabetes mellitus; Diabetic nephropathy; Epidemiology; HMO; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

ADULT; AGE; ALBUMINURIA; ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; DRUG USE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMOALBUMINURIA; POPULATION RESEARCH; RISK FACTOR; UNITED STATES;

AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 79952040419     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.11.022     Document Type: Article

References (20)

1. American Diabetes Association Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl. 1):S13-61.
2. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
3. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., Parving H.H., et al. Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl. 1):S79-83.
4. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49:S12-154.
5. Remuzzi G., Macia M., Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006, 17:S90-S97.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study (UKPDS) Group.
9. Valmadrid C.T., Klein R., Moss S.E., Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000, 160:1093-1100.
10. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
11. K/DOQI K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-266.
12. Ravid M., Brosh D., Ravid-Safran D., Levy Z., Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998, 158:998-1004.
13. Gall M.A., Hougaard P., Borch-Johnsen K., Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997, 314:783-788.
14. Forsblom C.M., Groop P.H., Ekstrand A., Totterman K.J., Sane T., Saloranta C., et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998, 21:1932-1938.
15. Rosen A.B. Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002. J Gen Intern Med 2006, 21:315-319.
16. Retnakaran R., Cull C.A., Thorne K.I., Adler A.I., Holman R.R. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006, 55:1832-1839.
17. Goldschmid M.G., Domin W.S., Ziemer D.C., Gallina D.L., Phillips L.S. Diabetes in urban African-Americans II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care 1995, 18:955-961.
18. Atta M.G., Baptiste-Roberts K., Brancati F.L., Gary T.L. The natural course of microalbuminuria among African Americans with type 2 diabetes: a 3-year study. Am J Med 2009, 122:62-72.
19. Newman D.J., Pugia M.J., Lott J.A., Wallace J.F., Hiar A.M. Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin Chim Acta 2000, 294:139-155.
20. Ginsberg J.M., Chang B.S., Matarese R.A., Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983, 309:1543-1546.